Compounds > ic 261

ic 261 and cki 7

ic 261 has been researched along with cki 7 in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (66.67)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cooper, CD; Lampe, PD1
Aulner, N; Durieu, E; Leclercq, O; Meijer, L; Notredame, C; Pescher, P; Prina, E; Rachidi, N; Späth, GF; Taly, JF1
Alessi, DR; Arthur, JS; Bain, J; Cohen, P; Elliott, M; Hastie, CJ; Klevernic, I; McLauchlan, H; Plater, L; Shpiro, N1
Caparrotta, L; Cozza, G; Gianoncelli, A; Meggio, F; Montopoli, M; Moro, S; Pinna, LA; Venerando, A; Zagotto, G1
Abadleh, M; Bischof, J; Hauser, D; Hirner, H; Knippschild, U; Laufer, S; Peifer, C; Schattel, V1
Feng, S; Ji, P; Li, GB; Ma, S; Sun, QZ; Wang, ZR; Yan, HX; Yang, LL; Yang, SY; Zou, J1

Other Studies

6 other study(ies) available for ic 261 and cki 7

ArticleYear
Casein kinase 1 regulates connexin-43 gap junction assembly.
    The Journal of biological chemistry, 2002, Nov-22, Volume: 277, Issue:47

    Topics: Animals; Casein Kinases; Cell Membrane; Cells, Cultured; Connexin 43; Gap Junctions; Immunohistochemistry; Indoles; Isoenzymes; Isoquinolines; Kidney; Phloroglucinol; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Rats; Recombinant Fusion Proteins

2002
Pharmacological assessment defines Leishmania donovani casein kinase 1 as a drug target and reveals important functions in parasite viability and intracellular infection.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:3

    Topics: Animals; Benzamides; Casein Kinase I; Conserved Sequence; Cricetinae; Female; Imidazoles; Indoles; Isoquinolines; Leishmania donovani; Leishmaniasis, Visceral; Macrophages; Mice, Inbred C57BL; Phloroglucinol; Sequence Alignment; Trypanocidal Agents

2014
The selectivity of protein kinase inhibitors: a further update.
    The Biochemical journal, 2007, Dec-15, Volume: 408, Issue:3

    Topics: Amino Acid Sequence; Animals; Cell Line; Drug Design; Enzyme Activation; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Recombinant Proteins; Spodoptera

2007
Identification of novel protein kinase CK1 delta (CK1delta) inhibitors through structure-based virtual screening.
    Bioorganic & medicinal chemistry letters, 2008, Oct-15, Volume: 18, Issue:20

    Topics: Anthraquinones; Casein Kinase I; Chemistry, Pharmaceutical; Computer Simulation; Drug Design; Drug Evaluation, Preclinical; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Molecular Conformation; Phosphorylation; Protein Isoforms; Software; Tyrosine

2008
3,4-Diaryl-isoxazoles and -imidazoles as potent dual inhibitors of p38alpha mitogen activated protein kinase and casein kinase 1delta.
    Journal of medicinal chemistry, 2009, Dec-10, Volume: 52, Issue:23

    Topics: Adenosine Triphosphate; Amino Acid Sequence; Animals; Binding, Competitive; Casein Kinase Idelta; Cell Line; Drug Discovery; Enzyme Inhibitors; Humans; Imidazoles; Inhibitory Concentration 50; Isoxazoles; Mitogen-Activated Protein Kinase 14; Models, Molecular; Molecular Sequence Data; Mutation; Protein Conformation; Rats; Trophoblasts

2009
Discovery of N6-phenyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine derivatives as novel CK1 inhibitors using common-feature pharmacophore model based virtual screening and hit-to-lead optimization.
    European journal of medicinal chemistry, 2012, Volume: 56

    Topics: Casein Kinase I; Diamines; Dose-Response Relationship, Drug; Drug Discovery; High-Throughput Screening Assays; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship

2012